These data also suggest that NF-κB inhibition by Bay117085 and resveratrol might have therapeutic potential regarding the suppression of CXCL10 in metabolic disorders, such as obesity/T2D, which involve systemic increases in inflammatory cytokine IL-1β. Here, CXCL10 is linked to Other metabolic disease.